Cargando…

Sex-Biased Immune Responses to Antibiotics during Anti-PD-L1 Treatment in Mice with Colon Cancer

Colitis is a frequently occurred side effect of immune checkpoint inhibitors (ICIs), which are increasingly used in cancer treatment, whereas antibiotics are widely used to treat colitis, their effectiveness in ICI-associated colitis remains controversial. In this study, we firstly assessed the effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jing, Nan, Wang, Luoyang, Zhuang, Huiren, Ai, Chao, Jiang, Guoqiang, Liu, Zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325566/ https://www.ncbi.nlm.nih.gov/pubmed/35903754 http://dx.doi.org/10.1155/2022/9202491

Ejemplares similares

Ultrafine Jujube Powder Enhances the Infiltration of Immune Cells during Anti-PD-L1 Treatment against Murine Colon Adenocarcinoma
por: Jing, Nan, et al.
Publicado: (2021)

Jujube Powder Enhances Cyclophosphamide Efficiency against Murine Colon Cancer by Enriching CD8(+) T Cells While Inhibiting Eosinophilia
por: Zhuang, Huiren, et al.
Publicado: (2021)

Biostimulating Gut Microbiome with Bilberry Anthocyanin Combo to Enhance Anti-PD-L1 Efficiency against Murine Colon Cancer
por: Liu, Xuerun, et al.
Publicado: (2020)

Enhancing therapeutic effects of murine cancer vaccine by reshaping gut microbiota with Lactobacillus rhamnosus GG and jujube powder
por: Jing, Nan, et al.
Publicado: (2023)

Promoting intestinal IgA production in mice by oral administration with anthocyanins
por: Liu, Xuerun, et al.
Publicado: (2022)

Downregulating testosterone levels enhance immunotherapy efficiency
por: Wang, Luoyang, et al.
Publicado: (2021)

Glycosylation of anthocyanins enhances the apoptosis of colon cancer cells by handicapping energy metabolism
por: Jing, Nan, et al.
Publicado: (2020)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
por: Lau, Janet, et al.
Publicado: (2017)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
por: Zhuang, Yuan, et al.
Publicado: (2020)

TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity
por: Ren, Yimeng, et al.
Publicado: (2021)

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
por: Zaslavsky, Alexander B., et al.
Publicado: (2020)

Male Sex Bias in Immune Biomarkers for Tuberculosis
por: Bothamley, Graham H.
Publicado: (2021)

Accounting for B-cell Behavior and Sampling Bias Predicts Anti–PD-L1 Response in Bladder Cancer
por: Dyugay, Ilya A., et al.
Publicado: (2022)

Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
por: Kim, Kyung Hwan, et al.
Publicado: (2020)

Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1(low) and immune desert-like mouse tumors
por: Ishikura, Nobuyuki, et al.
Publicado: (2022)

Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
por: Baxi, Shrujal, et al.
Publicado: (2018)

Abscopal effect of stereotactic radiotherapy combined with anti‐PD‐1/PD‐L1 immunotherapy: Mechanisms, clinical efficacy, and issues
por: Zhuang, Hongqing
Publicado: (2020)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

ZG16 regulates PD-L1 expression and promotes local immunity in colon cancer
por: Meng, Hui, et al.
Publicado: (2020)

RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination
por: Zhang, Yangyang, et al.
Publicado: (2023)

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
por: Kowanetz, Marcin, et al.
Publicado: (2018)

Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice
por: Garcia, Myrna G., et al.
Publicado: (2022)

Immunotherapy using anti-PD-1 and anti-PD-L1 in Leishmania amazonensis-infected BALB/c mice reduce parasite load
por: da Fonseca-Martins, Alessandra M., et al.
Publicado: (2019)

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
por: Tunger, Antje, et al.
Publicado: (2019)

Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents
por: Assi, Hikmat H., et al.
Publicado: (2021)

Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors
por: Giordan, Quentin, et al.
Publicado: (2021)

Boosting HSA Vaccination with Jujube Powder Modulating Gut Microbiota Favorable for Arginine Metabolism
por: Zhuang, Huiren, et al.
Publicado: (2023)

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
por: Chen, Jiming, et al.
Publicado: (2022)

The X in seX-biased immunity and autoimmune rheumatic disease
por: Jiwrajka, Nikhil, et al.
Publicado: (2022)

Sex-biased adaptive immune regulation in cancer development and therapy
por: Schafer, Johanna M., et al.
Publicado: (2022)

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
por: Poggio, Mauro, et al.
Publicado: (2019)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
por: Xu, Yiqi, et al.
Publicado: (2021)

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
por: Puccini, Alberto, et al.
Publicado: (2020)

Preclinical Evaluation of Recombinant Human IL15 Protein Fused with Albumin Binding Domain on Anti-PD-L1 Immunotherapy Efficiency and Anti-Tumor Immunity in Colon Cancer and Melanoma
por: Hsu, Fei-Ting, et al.
Publicado: (2021)

ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation
por: Wu, Youqian, et al.
Publicado: (2021)

Combinatorial therapy with an IL-15 superagonist (ALT-803) and anti-PD-L1 mAb augment T cell mediated anti-tumor immunity in mice
por: Johnson, Christopher B, et al.
Publicado: (2014)

Intestinal colonization with Candida auris and mucosal immune response in mice treated with cefoperazone oral antibiotic
por: Das, Diprasom, et al.
Publicado: (2023)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

PD-L1 dimerisation induced by biphenyl derivatives mediates anti-breast cancer activity via the non-immune PD-L1–AKT–mTOR/Bcl2 pathway
por: Zhang, Hua, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_78dj5g89lf80hl5j1d9m5e42pe